Metraipolis › archive › dc_fea2b49ef9b2

Two vs three cycles of neoadjuvant immunochemotherapy for resectable non-small-cell lung cancer: a real-world population-based study — Europe PMC PMID:41333472

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41333472
DOI
10.3389/fimmu.2025.1654830
License (as archived)
solo-consultazione
Archived
2026-11-08T12:38:55.171Z
SHA-256 of the archived text
ce020c312da80cf5a964a30b182c9cf597e77a8cf16091c931a7c22173b7609c
Stable URL of this page
https://metraipolis.com/documento/dc_fea2b49ef9b2

How to cite

Two vs three cycles of neoadjuvant immunochemotherapy for resectable non-small-cell lung cancer: a real-world population-based study — Europe PMC PMID:41333472 — Europe PMC (en), https://europepmc.org/article/MED/41333472 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fea2b49ef9b2 (Metraipolis archive dc_fea2b49ef9b2, sha256 ce020c312da80cf5a964a30b182c9cf597e77a8cf16091c931a7c22173b7609c)
BibTeX
@misc{dcfea2b49ef9b2,
  title = {Two vs three cycles of neoadjuvant immunochemotherapy for resectable non-small-cell lung cancer: a real-world population-based study — Europe PMC PMID:41333472},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41333472},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fea2b49ef9b2; sha256 ce020c312da80cf5a964a30b182c9cf597e77a8cf16091c931a7c22173b7609c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41333472. Agents can read the archived copy with the MCP tool read_document.